Nu Skin Announces Research Agreements With Stanford University and LifeGen Technologies
October 22 2009 - 3:00PM
PR Newswire (US)
Key Scientists Collaborate With Nu Skin on Genetically-based
Anti-aging Science PROVO, Utah, Oct. 22 /PRNewswire-FirstCall/ --
Nu Skin Enterprises, Inc. (NYSE:NUS) today announced that it has
entered into research agreements with Stanford University and
LifeGen Technologies, a genomics company based in Madison, Wis.
LifeGen co-founders, Richard Weindruch, Ph.D., and Tomas Prolla,
Ph.D., will also hold positions on the newly formed Nu Skin
Anti-aging Scientific Advisory Board. "Nu Skin has established a
25-year legacy of product innovation and our research agreements
with Stanford University and LifeGen Technologies add significant
fuel to our scientific engine," said Joseph Chang, Ph.D., Nu Skin
chief scientific officer and executive vice president of product
development. "We believe that these collaborative relationships
will help us develop next-generation skin care and nutritional
products from an enhanced understanding of the genetic basis of
aging." About Stanford Researchers at Stanford have focused on
profiling gene expression during human development and aging, and
have also explored novel modes of gene control in aging skin. Nu
Skin's agreement with Stanford aims to increase the understanding
of fundamental aging mechanisms in human beings by translating
insights from basic science into human application. The agreement
also includes access to Stanford's expertise in dermatological
clinical trials. About LifeGen Technologies Nu Skin will
collaborate with LifeGen in an exclusive agreement by leveraging
LifeGen's proprietary methods regarding gene expression profiling
and pathways affected by aging. LifeGen was co-founded in November
2000 by Drs. Weindruch and Prolla, professors at the University of
Wisconsin-Madison and leaders in the fields of gerontology and
genetics. The mission of LifeGen Technologies is to discover the
genetic basis of the aging process with the ultimate goal of
increasing a healthy life span. LifeGen's pioneering research has
resulted in several pending patents, and ongoing research
undertaken in collaboration with Nu Skin is expected to yield
further important intellectual property. LifeGen's patent for the
use of "gene expression profiling" as a method to measure the
progression of the aging process at the molecular level in
individual organs is expected to be a key component of the
partnership. The Company For 25 years, Nu Skin Enterprises, Inc.
has been demonstrating its tradition of innovation through its
comprehensive anti-aging product portfolio, independent business
opportunity and corporate social responsibility initiatives. Nu
Skin's scientific leadership in both skin care and nutrition has
established Nu Skin as a premier anti-aging company, evidenced in
its unique ageLOC(TM) approach and flagship products including the
Galvanic Spa® System II, Tru Face® Essence Ultra, LifePak® nano and
the g3 nutrition beverage. A global direct selling company, Nu Skin
operates in 48 markets worldwide and has more than 750,000
independent sales representatives. Nu Skin Enterprises is traded on
the New York Stock Exchange under the symbol "NUS." More
information is available at http://www.nuskinenterprises.com/.
Please note: This press release contains forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of
1934 that represent the company's current expectations and beliefs
regarding its research collaboration with LifeGen. The
forward-looking statements and related assumptions involve risks
and uncertainties that could cause actual results and outcomes to
differ materially from any forward-looking statements or views
expressed herein. These risks and uncertainties include, but are
not limited to, any risks that collaboration between the company
and LifeGen Technologies may differ from expectations and not
provide anticipated results or be able to be incorporated into new
products as planned. The forward-looking statements contained
herein are further qualified by a detailed discussion of associated
risks set forth in the documents filed by the company with the
Securities and Exchange Commission, including the company's Annual
Report on Form 10-K filed on February 27, 2009 and Quarterly
Reports on Form 10-Q filed on May 8, 2009 and August 7, 2009. The
forward-looking statements set forth the company's beliefs as of
the date of this release, and the company assumes no duty to update
the forward-looking statements contained in this release to reflect
any change except as required by law. DATASOURCE: Nu Skin
Enterprises, Inc. CONTACT: Jordan Karpowitz, +1-801-345-2187, , or
Kara Schneck, +1-801-345-2116, , both of Nu Skin Enterprises, Inc.
Web Site: http://www.nuskinenterprises.com/
Copyright